Nevertheless, our data strongly suggested that increasing nuclear PFN1 by inhibiting XPO6 could be a promising therapeutic approach to sensitize cancer cells, which frequently overexpress XPO640, to replication stress-inducing chemotherapies. This evidence concerns the gene PFN1 and cancer.